A number of other analysts have also recently weighed in on GPRO. Analysts at Robert W. Baird downgraded shares of Gen-Probe Incorporated from an “outperform” rating to a “neutral” rating in a research note to investors on Friday, May 4th. They now have a $83.00 price target on the stock. Separately, analysts at RBC Capital (NYSE: RY) downgraded shares of Gen-Probe Incorporated from an “outperform” rating to a “sector perform” rating in a research note to investors on Tuesday, May 1st. They now have a $82.75 price target on the stock, up previously from $72.00. Finally, analysts at ThinkEquity downgraded shares of Gen-Probe Incorporated from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, May 1st.
Gen-Probe Incorporated opened at 81.20 on Wednesday. Gen-Probe Incorporated has a 1-year low of $53.92 and a 1-year high of $86.96. The company has a market cap of $3.677 billion and a price-to-earnings ratio of 78.68.
Gen-Probe Incorporated last released its earnings data on Monday, April 30th. The company reported $0.55 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.51 by $0.04. Gen-Probe Incorporated’s revenue was up 7.3% compared to the same quarter last year. Analysts expect that Gen-Probe Incorporated will post $0.67 EPS next quarter.
Gen-Probe Incorporated (Gen-Probe) is engaged in the development, manufacture and marketing molecular diagnostic products and services, which are used primarily to diagnose human diseases, screen donated human blood, and ensures transplant compatibility.